Pluristyx has developed a clinical-grade manufacturing process for using a licensed Mad7 gene editing technology to block Human Leukocyte Antigen (HLA) markers expression. Humacyte is optimizing a ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue ...

Read here for an analysis on Humacyte (HUMA) stock post-Symvess approval, potential upside in revenue generation, and ...

DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology company valued at $567 million, has announced its intention to file an Investigational New Drug (IND) application with the U.S. Food and ...

Plans for filing an IND was agreed with the FDA in a recent meeting –– Positive preclinical results of the small-diameter ATEV were recently ...

NDAQ:HUMA) The Gross Law Firm Notifies Shareholders of Humacyte, Inc.(HUMA) of a Class Action Lawsuit and an Upcoming Deadline ...

Arteries are large blood vessels that carry oxygenated blood from the heart to the cells, tissues, and organs throughout the body. The subclavian artery is a major blood vessel located in the thorax ...

Symvess, or the ATEV™ (acellular tissue engineered vessel), is a first-in-class bioengineered human tissue that is designed to be a universally implantable vascular conduit for use in arterial ...

The vascular lesion triggers intravascular coagulation ... The so-called solitary necrotic nodule, consisting in acellular hyaline material, may represent the end-stage of sclerosing hemangioma.

there was a substantial risk to FDA approval of Acellular Tissue Engineered Vessel ("ATEV") for vascular trauma; and (4) as a result of the foregoing, defendants' positive statements about ...